SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

NEXT STORY
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
PREV STORY
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

UCHealth provides record $854 million in community benefits including $359 million in uncompensated care

author_avatar
NASDAQ Market News

Medical/Hospital Beds Market Worth $5.23 billion by 2027- Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

author_avatar
NASDAQ Market News

Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting

author_avatar
NASDAQ Market News